Data show that episodes of bleeding may often be observed in critically ill patients with
dialysis-dependent acute renal failure (ARF) on renal replacement therapy (RRT). From a
clinical perspective, patients with dialysis-dependent ARF and end-stage renal disease (ESRD)
may be considered a high risk population in regard to e.g. development of gastrointestinal
(GI-) bleeding.
In the current prospective subanalysis "SIREN" of the randomized placebo-controlled clinical
trial "SUP-ICU" (NCT02467621), the investigators seek to elucidate whether the subpopulation
of critically ill patients with acute kidney injury requiring renal replacement therapy (RRT)
benefit from prophylactic treatment with a proton-pump-inhibitor such as pantoprazole.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital Inselspital, Berne
Collaborators:
Rigshospitalet, Copenhagen, Denmark (Prof. Moller, Dr. Krag) SUP-ICU Principle investigator: Dr. M. Krag, Rigshospitalet, Copenhagen, Denmark SUP-ICU Sponsor: Dr. M.H. Moller, Rigshospitalet, Copenhagen, Denmark